News
-
Selpercatinib improves event-free survival in early-stage RET fusion-positive NSCLC
Alexander E. Drilon, MD, discusses the findings from the first randomized phase 3 trial to evaluate a RET kinase inhibitor as adjuvant therapy in RET fusion-positive lung cancer.
-
Intensive antiviral chemoprophylaxis in nursing homes reduces hospitalization
“The actionable message is not to aim for 100%; it is to reach the most residents in the first 48 hours,” said Viren Kaul, MD, FCCP.
-
Remote patient monitoring shows no benefit after serious infections, major trial finds
Researcher Sachin Yende, MD, MS, said the results challenge the assumption that remote monitoring alone improves postdischarge outcomes.
-
Limited data on GLP-1RAs show early promise in PAH
A review led by Benoît Aguado, MD, explores several mechanisms that could make GLP-1 receptors relevant to pulmonary vascular disease.
-
When PH and ILD meet: From overlap to a unified disease paradigm
For clinicians, the shift in the PH-ILD space demands a broader perspective that integrates vascular and parenchymal disease, emphasizes early detection, and prioritizes multidisciplinary care.
-
Study demonstrates superior protection from mRNA influenza vaccine compared with standard-dose vaccines
Experts caution that further research is needed to evaluate the platform’s performance across multiple seasons and compare it with enhanced vaccines.
-
Study supports 30 mL/kg or more of initial fluid for sepsis-induced hypoperfusion
Researchers also analyzed weight-based fluid resuscitation recommendations and found that, regardless of the approach, administration of 30 mL/kg of fluid was associated with reduced mortality.
-
Varenicline sampling with minimal guidance may boost smoking cessation rates
According to the investigators, the medication sampling model may lower barriers to engagement and allow patients to consider cessation on their own terms.
-
Short-course all-oral therapy appears effective, safe for resistant TB
Patrick PJ Phillips, PhD, said the noninferiority BEAT Tuberculosis trial showed a six-month treatment strategy could achieve outcomes similar to those of longer, standard regimens.
-
Ensitrelvir cuts COVID-19 risk by two-thirds after household exposure
Paul E. Sax, MD, said postexposure prophylaxis may be a useful addition to vaccination, testing, and treatment, particularly in populations at high-risk of severe disease.
